BioScrip (BIOS) Given Daily News Sentiment Rating of 0.35
Media headlines about BioScrip (NASDAQ:BIOS) have trended positive on Monday, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioScrip earned a news impact score of 0.35 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.9427291846902 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Attention Seeking Stock – BioScrip Inc (NASDAQ: BIOS) – Alpha Beta Stock (alphabetastock.com)
- BioScrip Announces US Congress Passage of Medicare Home Infusion Transition Benefit, Effective 2019 – Business Wire (press release) (businesswire.com)
- BioScrip (BIOS) Raised to “Buy” at BidaskClub (americanbankingnews.com)
- BioScrip Announces U.S. Congress Passage of Medicare Home Infusion Transition Benefit, Effective 2019 (finance.yahoo.com)
- Volatile Stock in List: Bioscrip Inc (BIOS) – Emn News (emnnews.com)
A number of brokerages have commented on BIOS. Zacks Investment Research upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. BidaskClub upgraded shares of BioScrip from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. SunTrust Banks set a $4.00 price target on shares of BioScrip and gave the company a “buy” rating in a research report on Thursday, December 21st. Finally, ValuEngine upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $3.63.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.